Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$171K Buy
4,792
+814
+20% +$25.7K 0.01% 1458
2026
Q2
$109K Buy
3,978
+561
+16% +$14.9K ﹤0.01% 1748
2026
Q1
$91.7K Sell
3,417
-1,338
-28% -$40.1K ﹤0.01% 1753
2025
Q4
$146K Buy
4,755
+1,773
+59% +$55.3K 0.01% 1270
2025
Q3
$91.5K Buy
2,982
+1,063
+55% +$25.9K 0.01% 1563
2025
Q2
$39.6K Buy
1,919
+209
+12% +$4.29K ﹤0.01% 2066
2025
Q1
$33.5K Sell
1,710
-429
-20% -$9K ﹤0.01% 2073
2024
Q4
$44.6K Buy
2,139
+1,051
+97% +$23.1K ﹤0.01% 1745
2024
Q3
$26.5K Buy
1,088
+335
+44% +$8.96K ﹤0.01% 1932
2024
Q2
$18.9K Sell
753
-382
-34% -$10.8K ﹤0.01% 1894
2024
Q1
$33.9K Buy
1,135
+749
+194% +$22K 0.01% 1288
2023
Q4
$10.7K Buy
+386
New +$12.1K ﹤0.01% 1868

Other funds holding GMAB

GAMMA Investing's GMAB Position: Q3 2026 in Review

GAMMA Investing increased its Genmab (GMAB) stake by 20% in Q3 2026, buying an estimated $25.7K and bringing the position to 4,792 shares worth $171K. The position accounts for 0.01% of the portfolio, ranked #1458.

GAMMA Investing first reported a position in GMAB in Q4 2023 and has held it in 12 quarters since. 13 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • GAMMA Investing held 4,792 shares of Genmab worth $171K as of Q3 2026.
  • GAMMA Investing bought 814 Genmab shares in Q3 2026, an estimated $25.7K.
  • Genmab made up 0.01% of GAMMA Investing's portfolio in Q3 2026, its #1458 holding.
  • GAMMA Investing first reported a position in Genmab in Q4 2023 and has held it in 12 quarters since.
  • 13 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.